35 Burst results for "Biogen"

"biogen" Discussed on Fading Memories: Alzheimer's Caregiver Support

Fading Memories: Alzheimer's Caregiver Support

02:21 min | Last month

"biogen" Discussed on Fading Memories: Alzheimer's Caregiver Support

"We start with the, the warning signs of Alzheimer's. What's what's an actual warning sign? And what is actual related to normal aging? Which is actually having this conversation with our friends. Last night, really good friend has a tendency to do about 15 things at once, and can't seem to remember what she's doing. And I think I know for because it hasn't changed in fifteen years that that's just life is and not paying attention. So we're can we start there? Sure. So, you know, there's certainly as we get older and our brain shrinks, we start off some capacity, some cognitive capacity that is, you know, considered the normal aging process, but you know, in today's day and age, we really give very little leeway for that just to remind people, you know, our grandparents, you know, in the 1960s, 70s 80s as they got older, they became senile and that word is really fallen out of favor. So we don't really talk so much about senility as the diagnosis or excuse for having, you know, poor memory or or function. It's not to say that the dog. Not any change that occurs with aging but we really won't get towards. Is there more of a problem. And when we start thinking about dementia, which is the big umbrella term that we think about and, and Alzheimer's disease being the most, common one, there has to be memory loss. So that's a that's, that's a symptom and assigned really, that has to be there. And then there has to be some sort of dysfunction in other what we call spheres of cognition, and probably the easiest one that to talk about is something called executive functioning. So when you go see a neurologist Thursday, we are you know, you're going to be asked questions about who does the who does the bills at home? What are what are the what are the what's the capacity to pay the bills and somebody who may be paid bills forever in their adult life? And all of a sudden now a spouse or a child has to double-check. There's late payments. There's overdrawn on a checking accounts things like that is the ability to sort of have this high-level executive wage. Ocean is a is really a sign that there's something perhaps going on, much more than just. Oh, I can't remember that

Alzheimer's biogen
Q2-2021 Biotech Earnings, Commercial-Stage Biotech Suffers

Breaking Biotech

01:59 min | Last month

Q2-2021 Biotech Earnings, Commercial-Stage Biotech Suffers

"And the first company. I want to talk about is by jin which is a real favorite of mine ticker symbol b. I believe and they're sitting at a fifty billion dollar market cap and what we heard is that they announced q to revenue of two point. Seven eight billion dollars and this is compared to twenty twenty cutie revenue of three point six eight billion so huge decline there and that is mostly due to a decrease in their ms revenue of twenty four percent year over year. And if you remember. When i went through the biogen episode i did. The majority of their revenue comes from their ms franchise and since the lawsuit against by jin was in favor of the generic companies including mylan they have launched generic versions of tech der which are now at risk because by genus filed an appeal. And what this means is that these generic companies are going to be able to sell their generic version of tech era at the risk of biogen winning on appeal in which case Going to be able to litigate against them for patent infringement. So during this time at which we don't know what the status of the appeal is gonna be biden's gonna start losing. Ms franchise market share pretty quickly to these generic companies. So we're starting to see this now with these abysmal. M s numbers now. The company did increase their guidance for the rest of the fiscal year. Only by about two hundred to three hundred million dollars so not a huge amount but they said that. This is due to better-than-expected ms sales. So who knows what's going on there but really the bulk of the call was the excitement around the addy home commercialization efforts and now just to say the amount of home revenue was only like one or two million dollars so very much a drop in the pan not very impressive so far. But it's because all of these infrastructure efforts need to take place in order to get hospitals up and running in order to treat patients

JIN Biogen Mylan Biden
The Quest for a Covid Pill

The Readout Loud

02:12 min | 2 months ago

The Quest for a Covid Pill

"You guys had a great story this week along with nick. Floor co about billy. Done the the regulator kind of at the heart of The helm controversy What did you guys find out about him as you were reporting this. Well what's interesting is we learned quite a bit. Because for anyone. Who's paid attention to this and might have cursorily google billie dunn. You'd find that there's very little information about him on the internet and so that was kind of the mountain that we're gazing up at As we embarked on this because as you mentioned he does seem to have emerged as really the key person at fda Who biogen identified as being you know willing to embrace their read of the very controversial data and that that set in motion the process by which the drug was eventually approved. And i think the narrative around the time of the approval and based on his comments at a public meeting last year was that he was really drinking the kool aid. That this guy you know maybe was kind of a mark for biogen. Maybe kind of went over his skis or listen to closely to patient advocates at the expense of the kind of rigorous view of data that one might expect from the fda. But what. I thought was interesting. Reporting it out and we talked to quite a few people who've worked with him whether add fda or At companies that had been before him or or in patient advocacy groups that have likewise met with him and would almost everybody said was that he built this reputation as a very stern and rigorous regular someone who demanded very clean very compelling data from treatments. That might win approval before even considering them in the sense that it gave him a lot of respect among his colleagues at fda and in some cases it really frustrated or even angered patient advocates. Who thought that you know for diseases like ls for example where there are so few options that he should ease up on that standard and so in those conversations that i think we had our. You can speak to this eventually. You'd get too. So what do you think of the agile. Home approval and people seemed kind of baffled. The a lot of people said like that's not the billy done. I know i remain confused. As to how he was won over by this data set from biogen. When i know him as a person who takes a completely different approach to regulating new drugs.

Billie Dunn Biogen FDA Billy Nick Google
Biogen Shares Down 7%

News, Traffic and Weather

00:17 sec | 2 months ago

Biogen Shares Down 7%

"Today. That's after United Health Group said it needed more time to determine its coverage policy for the biotech companies recently approved $56,000 Alzheimer's disease, drug addled film that's expected to raise costs for the U. S government's Medicare program. It's official. The Emerald

United Health Group Alzheimer's Disease U. S Government
Medicare Evaluating Coverage for $56,000 Alzheimer's Drug

AP News Radio

00:52 sec | 2 months ago

Medicare Evaluating Coverage for $56,000 Alzheimer's Drug

"Medicare's lunch the process to decide if it will cover the cost of a new controversial Alzheimer's drug that's undergoing congressional scrutiny the new drug ad you helm is costly fifty six thousand dollars a year and there are questions still surrounding who it will help after the FDA had to scale back its recommended use right now Medicare's making case by case decisions on whether to cover the drug it may have a blanket answer sometime next year meanwhile Congress is intensifying its scrutiny of the drug's approval to committees of requested documents from drugmaker Biogen including those surrounding unusual contacts between company executives and FDA regulators there was a new analysis done after company study suggested add to home was ineffective at slowing mental decline Jackie Quinn Washington

Alzheimer's Drug Medicare FDA Drugmaker Biogen Congress Jackie Quinn Washington
FDA Calls for Investigation Into Alzheimer's Drug Approval Process

News and Perspective with Taylor Van Cise

00:31 sec | 2 months ago

FDA Calls for Investigation Into Alzheimer's Drug Approval Process

"The approval of a controversial new Alzheimer's drug. In a letter sent to the health and Human Services Inspector General Janet Woodcock asks for an independent review into the interactions between drugmaker Biogen representatives at the FDA Woodcock alleging that there may have been communication between the FDA and Biogen during the review process that goes against FDA policy. Biogen's new Alzheimer's drug received FDA approval in early June despite an advisory committee previously questioning its efficacy. ABC News is next get more out of

Alzheimer's Drug Health And Human Services Insp Biogen Janet Woodcock FDA Abc News
FDA Head Calls for Inquiry Into Alzheimer's Drug Review

AP News Radio

00:42 sec | 2 months ago

FDA Head Calls for Inquiry Into Alzheimer's Drug Review

"The FDA wants an independent watchdog to take a closer look at the decision making behind the conditional approval of a new Alzheimer's drugs that can reduce brain plaque but hasn't been proven to reverse the disease the acting head of the food and drug administration Dr Janet woodcock is calling for a government investigation into the contacts between your agency's drug reviewers and the maker of a controversial new else Hymers drug ad you help the announcement made via Twitter comes just a day after the FDA took the unusual step of scaling back prescribing information on the drug last month the health news site stat reported on it usually close collaboration between a top executive and the FDA's lead reviewer for Alzheimer's drugs Biogen has pledged to cooperate with the inquiry Jennifer king Washington

Alzheimer's FDA Dr Janet Woodcock Hymers Twitter Biogen Jennifer King Washington
FDA Grants Accelerated Approval for Alzheimer's Drug

The Readout Loud

01:25 min | 2 months ago

FDA Grants Accelerated Approval for Alzheimer's Drug

"So what would this pike. Sp if it didn't start with an update on adam damian's favorite drug guys. There's more news on that front this week. Catch us up right so the hot off. The presses aspect came out just thursday morning which is that. The fda restricted the label for which you helm is approved basically advising doctors to prescribe the drug solely to patients who mostly matched the population in which it was studied in face retrials this. I mean the implications of this we can. We can kind of talk about but you know one of the shocking things really probably to me. The most shocking thing on the day that agile home was approved was the breadth of the fda's label. The drug was indicated for anyone with alzheimer's disease at any stage of the disease regardless of what their sort of brain biology was. And as we know this drug is meant to clear out plaques from the brain that purported to contribute to the advanced alzheimer's and so that label was was fairly galling honestly and so the fda mostly walking it back to what people had expected for those people who even expected approval. was interesting. I feel like it might have fewer implications for the way the drug is actually used. Because i think that physicians indefinitely biogen were thinking that that it would only go to to this narrower group of patients but maybe just has more more implications for our fixation on the fda and what is going on there.

Adam Damian Alzheimer's FDA Biogen
Eli Lilly Stock Jumps, Biogen Drops on Alzheimer's Treatment Approval

PM Tampa Bay with Ryan Gorman

00:21 sec | 3 months ago

Eli Lilly Stock Jumps, Biogen Drops on Alzheimer's Treatment Approval

"Could get cheaper price tag of $56,000 a year was set by Biogen for its treatment. But now a drug by Eli Lilly has been fast tracked by the FDA and the competition's expected to drive prices down. Word of the competition drove Biogen Stock down 6% Eli Lilly jumped 7%. Google

Biogen Eli Lilly FDA Biogen Stock Google
Backstory: FDA Approval of First Alzheimer's Drug is Mired in Controversy

Motley Fool Money

02:09 min | 3 months ago

Backstory: FDA Approval of First Alzheimer's Drug is Mired in Controversy

"Let's move this and talk about treatment for another health challenge. Alzheimer's shares of biogen are up forty percent in the month of june. Because the fda approved biogen's drug to treat alzheimer's this is the first medication aimed at slowing cognitive decline. For people with alzheimer's that regulators have approved and yet it is not without controversy. Three members of the fda advisory panel resigned over the decision. There are a couple of threads to get to here. But i guess my first question is what is going on here is like. Was this a mistake to green. Light this treatment. Well a chris. I call this nearly biotech soap opera. You can even bring in greek mythology here. first of all biogen's drug is like the mythical phoenix it. Literally rose from the ashes. I mean this was a drug that not all that long ago had been relegated to the trash heap seemingly failing late stage clinical studies badgen later came back and did some further analysis and analysis and they said hey you know we. We actually see that. There's a potential here and they they pursued and then ultimately did file for fda approval and ultimately won. But you're right it's extremely extremely controversial. The fda's advisory committee that was convened to review. The data came back and voted ten against recommending approval. One abstention no member of that committee voted in favor of this drug being approved. They thought that another clinical study needed to be conducted to to establish that the drug was actually effective. And so and and not even just that several members of the committee wrote op eds publicly urging the fda not to go ahead and approve. Distract the fda. Did it anyway. And so it's extremely

Biogen Alzheimer FDA Badgen Phoenix Chris
Biogen's New Alzheimer's Drug Is a Medicare Budget Buster

The KFBK Morning News

01:55 min | 3 months ago

Biogen's New Alzheimer's Drug Is a Medicare Budget Buster

"New drug for Alzheimer's comes with rather controversial approval, and now we're learning a huge price tag. The drug is called Adele Adele home, I should say adult film. It was approved by the FDA last week. It's $56,000 per year for a supply. Medicare copays could reach $11,000. The Alzheimer's Association's sharply criticized the manufacturer, Biogen for that price tag. You're about to hear from Paul Seagirt. He is with PCs advisers there in Northern California firm. They help businesses manage health care costs, And he says, This is a perfect example of what is wrong with how we approve and distribute drugs. We've got great health care how we pay for? It's crazy. This is a perfect example. You've got a $56,000 drug that the FDA is just approved. Three of the scientists who were on the review panel That made a recommendation to the FDA have resigned because of the 11 in November, 10 said. No, I'm recommending to approve it and one said, I don't know. And yet they still approved a drug that Has, you know, really hasn't shown itself to be effective. They're going to build $56,000. A year for each person that's on this drug. It's incredible. The FDA advisory board gave the thumbs down to this drug. Yet it got approved by the agency. The question is why It's a great question, and unfortunately, I There's a lot of financial drivers that drive our whole system. I'm a free market person. I'm not against that. But we've a lot. We're approving this thing and then saying we're going to allow them to do a nine year confirmatory trial. Which in those nine years if they do end up confirming that it is not Very effective or not that effective or not at all, effective. We're gonna have spent hundreds of billions of dollars at that time frame. We're

Adele Adele FDA Alzheimer's Association Paul Seagirt Biogen Alzheimer Northern California
Medicare Copays for New Alzheimer's Drug Could Reach $11,500

AP News Radio

00:49 sec | 3 months ago

Medicare Copays for New Alzheimer's Drug Could Reach $11,500

"A new drug it's been shown to reduce clumps of plaque in the brain could become the most costly medication covered by Medicare add your home from drugmaker Biogen is the first new Alzheimer's medication in nearly twenty years the company's price the intravenous medication at fifty six thousand dollars a year a new analysis from the Kaiser family foundation says the cost of the drug would raise Medicare premiums broadly and that some older patients could be looking at co payments of about eleven thousand five hundred dollars annually Medicare hasn't made a formal determination on covering at your home the Kaiser report estimated that it just happened million Medicare recipients are prescribed the drug it'll cost the program nearly twenty nine billion dollars a year the drug has sparked controversy over its price tag and questionable benefits several members of an FDA advisory panel that oppose the drug resigned over the agency's decision to approve it I'm Jennifer king

Drugmaker Biogen Medicare Kaiser Family Foundation Alzheimer Kaiser FDA Jennifer King
"biogen" Discussed on The Readout Loud

The Readout Loud

06:50 min | 3 months ago

"biogen" Discussed on The Readout Loud

"Hours of recording time and and days of actual time getting ready for the thing. That happened monday. Which was the. Fda's decision on biogen's polarizing alzheimer's drug now called agile helm and as you heard earlier episode and has probably had heard prior to listening to it. The fda decided to approve that drug. I have to say. Monday was kind of exciting when the approval actually happened. I mean there was. There was adrenalin flowing and it was a surprising approach that the fda took it wasn't just an approval or rejection. It was an approval but under a surprising pathway. Maybe damian break it down for us. Yes so the. Fda has at its disposal. This concept of accelerated approval and is quite often used for new treatments for cancer. And so what. The fda will do in the name of getting new treatments to patients as quickly as possible is approved drug based on what they call a surrogate endpoint which is basically evidence that the drug does a thing that is likely to predict a thing that we all want so in cancer. That means you can get a drug approved shrinks tumors even if we don't yet know whether it prolongs survival for patients with cancer and that's because you know it's pretty well established that the fewer tumors you have or smaller whatever the healthier you will be so the teen this approach to As you helm as it's now called but in this case it isn't as cut and dry shrinking tumors. They approved it. Based on its ability to decrease levels of beta amyloid in the brain the toxic plaques. That are i was gonna say believed hotly debated the role that they play in the actual progression of alzheimer's disease. And so this is where as you can probably imagine. The controversy comes into play. Because by the fda's logic the fact that you can reduce these amyloid plaques means that it's likely to Slow the progression of alzheimer's for patients who take it but the rub is that biogen ran to very large trials keeping tabs on the cognitive abilities of patients in the study and as you probably know one was narrowly positive and one failed so to people looking at this from the outside. It seems like the fda found a compromise that might not have the strongest logical basis. Yeah i mean. I think that was probably the biggest surprise came out of monday. I mean i think. A lot of people expected the fda to approve. Adam just not leave sort. They are damian. I i know you thought that they would. It would happen. And i was kind of leaning in that direction. I'm but again this. This are curveball. This accelerated approval. Pathway is really interesting because again first of all you know that that pathway has never been used for a neuro degenerative disease before news alzheimer's and and the fact is that the kind of went about it. Like you said damian backwards in that we already have two large clinical trials with very mixed results on the clinical benefit. Endpoint point that people care about most in alzheimer's and but fda sorta through that out and said all right. Just by the fact that this drug clears bid amyloid plaques from the brain which really nobody disputes. I mean the data are pretty clear that this drug does that but what is completely unclear and unknown And i think a lot of people doubt is that whether that actually leads to cognitive improvement in patients to be that was the most interesting part of the entire thing was that the fda was essentially saying yup we believe in the amyloid hypothesis. That idea that by clearing amyloid you will affect the The progression of the disease and that is just incredibly controversial. And as you guys pointed out during the advisory committee meeting the fda actually made the statement that they were not using amyloid as a surrogate for disease progression and then they turned around and did exactly that and so that led to a tremendous amount of backlash from the advisory committee which voted no on whether these data supported approval. Yeah i think the other the other big surprise On monday was the price right By has set the price of home at fifty six thousand dollars a year. that's the sticker. Price of it will be discounted down once serve insurer. Discount in medicare discounts get factored in. But that is a what is that five times. What kind of people expected the drug people were kind of looking at like ten to twelve thousand dollars a year drug fifty. Six thousand dollars is huge. So i just want to say i actually. Who's not surprised by this price at all i. It was probably because they didn't do enough research beforehand. And i was surprised by surprise at the price because think about what kind of drug this is. I mean it's a biologic drug. They've been working on it for years. It it seems to me more along the lines of these speciality drugs which is exactly the way biogen has been positioning it and in the messaging since they announced the price talking about it in that way you have analysts comparing it to the existing alzheimer's medicines which cost something like eight thousand dollars a year but the existing alzheimer's medicines don't act on the underlying cause of the disease debate about whether i can't imagine does as well but it's a totally different category of drug and to me. I was just not surprised at all. I would've been shocked if they price it at ten thousand dollars a year. It's just not what buying does. Yeah no that's fair. And i was surprised but i think that reflects my own personal ignorance because i think it gets to magazine said there was a discrepancy in terms. Of how a lot of people on the analysts were thinking about it and how biogen was thinking about it on the analyst. People were looking at it as some people were looking at has a primary care drug that you know you would. You would see your primary care physician and get diagnosed with alzheimer's and then be put on this drug immediately. And thus there'd be a really wide net that biogen would be casting and that would assume you'd wanna lower price which you could make more money on because you get a higher number of patients by engine. I think looked at all of the facts of the drug. Like you said it's a biologic but also it needs to be administered. In infusion center patients will very likely need to get pet scans and is before they even get on the drug and then probably need pet. Scans throughout so i think biogen realize it was going to be much smaller patient population. That was going to get this drug. Then maybe a lot of people thought and probably kind of worked backwards to get to that fifty six thousand dollar number because then you're looking not not at a rare disease thing but as you said as a specialty medicine which tend to be more expensive because companies expect you know smaller number people to get them and thus if you wanna make profits which biogen is absolutely poised to do at this point you have to charge a premium price but this for exists to surprise number three. The label adam. Oh yeah we're all over this. Explain the surprise in the label will. Yeah you know often hundre when we when we get these truck approvals. Everyone goes to the label. The fda approved labeled to kind of just look sort of what the details are. What's included what's not included when we looked at the label for our home. The fda label says that it's a treatment for alzheimer's it doesn't say it's a treatment for patients with early stage alzheimer's or you know or cognitive early..

Six thousand dollars ten monday Monday fifty six thousand dollar five times Adam drug fifty ten thousand dollars a year eight thousand dollars a year Fda fifty six thousand dollars a y twelve thousand dollars a year biogen two large clinical trials fda amyloid number three alzheimer damian
"biogen" Discussed on Here & Now

Here & Now

01:32 min | 3 months ago

"biogen" Discussed on Here & Now

"But <Speech_Female> the fact that the report <Speech_Female> relied on private <Speech_Female> documents that <Speech_Female> were apparently leaked to <Speech_Female> the press. <SpeakerChange> <Speech_Female> Do you think anything happens <Silence> next. <Speech_Male> That's <Speech_Male> difficult to say. I obviously <Speech_Male> imagined that the <Speech_Male> irs is going to be looking <Speech_Male> at this rather aggressively <Speech_Male> what they <Speech_Male> find. <Speech_Male> We'll determine where they go <Speech_Male> from there. I've <Speech_Male> seen at least speculated <Speech_Male> that irs <Speech_Male> servers might have been had. <Speech_Male> But it's it's <Speech_Male> difficult <Speech_Male> to say until <Speech_Male> we hear more back from <Speech_Male> the irs. <SpeakerChange> As to what they found <Speech_Female> and <Speech_Female> you once worked <Speech_Female> in the tax analysis division <Speech_Female> of the congressional <Silence> budget office. <Speech_Female> What kind <Speech_Female> of impact does it have. <Speech_Female> When <Speech_Female> such <Speech_Female> wealthy <Speech_Female> wealthy people <Speech_Female> avoid <Speech_Female> or <Speech_Music_Female> heart required <Speech_Female> to pay <Speech_Female> taxes <Speech_Music_Female> affect us it have on <Speech_Music_Male> the federal <SpeakerChange> budget. <Speech_Music_Male> Well <Speech_Male> obviously it lowers the <Speech_Music_Male> federal revenues. <Speech_Music_Male> There's a considerable <Speech_Music_Male> amount of <Speech_Music_Male> unrealized capital <Speech_Music_Male> gains. It's not being <Speech_Music_Male> taxed so yet has <Speech_Music_Male> some effect on the budget. <Speech_Music_Male> Still <Speech_Music_Male> both money being earned <Speech_Music_Male> through salaries and <Speech_Music_Male> wages so most <Speech_Music_Male> of it's still being tax <Speech_Music_Male> is just at <Speech_Music_Male> the very top end <Speech_Music_Male> that <Speech_Music_Male> will or not being taxed <Speech_Music_Male> on the increase in their <Speech_Music_Female> wealth. <SpeakerChange> <Speech_Music_Female> Mcclellan <Speech_Female> <Advertisement> senior fellow in <Speech_Music_Female> <Advertisement> the urban brookings tax <Speech_Music_Female> <Advertisement> policy center. <SpeakerChange> <Speech_Music_Male> <Advertisement> Thank you <Speech_Music_Male> <Advertisement> thank for <Speech_Music_Male> <Advertisement> having me. <Speech_Music_Female> <Advertisement> Hope <Speech_Music_Female> <Advertisement> that cleared things up <Speech_Music_Female> <Advertisement> here now <Speech_Music_Female> <Advertisement> is production of npr <Speech_Music_Female> <Advertisement> and wvu aren't association <Speech_Music_Female> <Advertisement> with the bbc <Speech_Music_Male> <Advertisement> world service. <SpeakerChange> I'm <Speech_Music_Male> <Advertisement> robin young. <Speech_Music_Male> <Advertisement> And i'm peter o'dowd <Speech_Music_Male> this is here now <Music> <Music> <Music> <Music> <Music> <Music> <Music> <Music> <Music> <Music> <Music> <Music> <SpeakerChange> <Speech_Music_Male>

"biogen" Discussed on Here & Now

Here & Now

02:59 min | 3 months ago

"biogen" Discussed on Here & Now

"Percent capacity. You can eat inside a restaurant now. Outdoor cafes opened about ten days ago the weather has been gorgeous and people are just thronging them outside and another important thing. The curfew daily curfew from nine pm yesterday was pushed to eleven pm. So you can sorta have a regular evening out and yeah like you said. The biggest news is vaccinated. Europeans and americans can now come back to france. Parisian's must have a spring in their step today. They do they really do any concerns at all about another wave not immediately. i mean. they're really right now. Pushing vaccines and the vaccinations are going very. Well they're open to everyone except children. The head of the scientific authorities said yesterday. He's cautiously optimistic. And says the summer is going to be calm but you know he did say be careful. We could have a fourth wave next fall. Remember last summer everybody thought it was over and it came roaring back in october. But even if it did it would be different. This time forty. Two percent of the french today are fully vaccinated and eighty percent of those considered vulnerable are now vaccinated so that would protect the country. If there were a resurgence of the mirus well such different story when you compare it to brazil where phillies look in india. Where lauren is reporting today. Lauren what does the political picture look like in india. Especially how is prime minister. Narendra modi fair. And he was under a lot of pressure when things were spiralling out of control if things improved for him. There's still a lot of anger even among own. Supporters is approval. Ratings have fallen. It's hard to know whether that'll be sustained. The next election is in three years. It's like a lifetime in politics and modi's the most popular leader in india in decades and also the opposition is kind of in shambles. There isn't really a strong opposition to him. He addressed the nation earlier this week on tv for the first time. Actually since april when cases started to skyrocket and he defended his government's performance he said india's vaccination program is the envy of the world. A lot of health. Experts will dispute though speaking politics. Eleanor i to ask you about what happened to french. President emmanuel macron and. This was czar incident on tuesday slapped in the face while greeting a crowd of people. I mean. there's probably doesn't have anything to do with the pandemic but but how. This flare on the slapper. He goes on trial today so very quick trial. Everyone was shocked and being seen as not just an attack on him. But on the french presidency civil discourse and democracy itself it's being compared in small way to the storming of the us capital in january. But i can tell you something. That's really different is im- there was immediate and unanimous condemnation and outrage from politicians across the political spectrum from far left to far right even far right leader mcconnell's main opponent marine le pen. Said this is shocking. We can never violence. We have to fight each other politically.

india Lauren eighty percent Two percent april january lauren tuesday france yesterday Narendra modi eleven pm brazil october mcconnell last summer nine pm yesterday three years today forty
Alzheimer’s Drug Likely to Be FDA Approved Despite Potential Risks

Afternoon News with Tom Glasgow and Elisa Jaffe

00:44 sec | 3 months ago

Alzheimer’s Drug Likely to Be FDA Approved Despite Potential Risks

"Drug is reasonably likely to result in a clinical benefit and granted approval. Despite potential risks. NBC's Brian Clark with details The FDA s decision to grant accelerated approval to Biogen's new Alzheimer's drug is a historic first in the fight against the disease. It's not a cure. It's not a panacea, but it is a first line treatment that that does look at the underlying cause of the disease. Dr. Joanne Pike, the chief strategist of the Alzheimer's association, points out Alzheimer's remains a fatal disease. We have to have a first line treatment before we can get to a second line or a third line, Dr Pike says. This requires the health care system do prioritize Early detection. Brian Clark ABC News The Department of Justice

Alzheimer's Drug Brian Clark Biogen Dr. Joanne Pike Alzheimer's Association NBC Alzheimer's FDA Fatal Disease Dr Pike Abc News Department Of Justice
FDA Approves Much-Debated Alzheimer’s Drug Panned by Experts

AP News Radio

00:48 sec | 3 months ago

FDA Approves Much-Debated Alzheimer’s Drug Panned by Experts

"The food and drug administration approved the first new drug for Alzheimer's disease in nearly twenty years but there were doubts the drug is from Biogen magic can amount which is now could be marketed as and you held the FDA approved the drug saying it was based on results that seems reasonably likely to benefit Alzheimer's patients Dr Maria Correo is chief science officer with the Alzheimer's association this therapy slows the progression of the disease because it addresses the underlying biology one of the hallmarks of Alzheimer's which is amyloid plaques therapy usually manages symptoms of Alzheimer's like insomnia or anxiety FDA advisor Dr Caleb Alexander said no to the drug's approval he said the agency has regulatory standards based on evidence but in this case he thinks the product get a pass at Donahue Washington

Alzheimer's FDA Dr Maria Correo Alzheimer's Association Biogen Dr Caleb Alexander Insomnia Washington
First New Drug for Alzheimer's in 20 Years Approved by FDA

AP 24 Hour News

00:16 sec | 3 months ago

First New Drug for Alzheimer's in 20 Years Approved by FDA

"And Drug Administration approved the first drug they say may help slow Alzheimer's disease. It's a surprise decision. The FDA is independent advisor said the treatment hadn't been shown to help treat Alzheimer's. The drug from Biogen is the first new Alzheimer's treatment in nearly 20 years, The

Alzheimer's Drug Administration FDA Biogen Alzheimer's Treatment
Alzheimer’s Drug From Biogen Wins US Approval

Bloomberg Businessweek

00:24 sec | 3 months ago

Alzheimer’s Drug From Biogen Wins US Approval

"Service prices as we're seeing activity picking up Biogen has received approval for its controversial Alzheimer's disease, their appeal landmark decision that stands to dramatically change treatment for the debilitating brain condition. Bijan shares up now by 40.2%. Japan's A Sigh is working with Bijan on the Alzheimer's drug. It's a TRS are also surgeon today.

Alzheimer's Disease Biogen Bijan Alzheimer's Drug Japan
FDA Approval of New Alzheimer’s Drug May Boost Prospects

The Readout Loud

02:09 min | 4 months ago

FDA Approval of New Alzheimer’s Drug May Boost Prospects

"Today. I think really take this week on reading. The the fda tea leaves of drug approved ability. We'll thank you. Say but yeah. I think you know we are basically on the eve of what is expected to be. This momentous decision by the fda on canyon have the controversial alzheimer's disease treatment from biogen and because there isn't really much to do in terms of trying to predict that decision. There isn't much information to pick apart. I think people you know resort to to what we all would which is maybe not quite tinfoil hat but we look at whatever evidence there is and try to construct a take and so for months. I think there's been this. Focus especially in the investor community on parsing each individual. Fda decision for clues as to some sort of like meta take on how the agency is thinking about new drugs. Yeah i mean you know. There's this idea right like you know is the fda being more conservative would drag approvals. Is it being more flexible. Which approvals right and it has come to feel a little bit absurd so if there's a run of as there were a few months ago surprising decisions whether it be Rejections or you know. Advisory committee hearings called where they weren't previously expected then. Suddenly the vibe is oh well. They're really cracking down. And then recently we had to Drug approvals in consecutive weeks. That came through. Let's say favorably to the drug companies and sort of undramatically so then the vibes us the fda in fact. They've kind of taken their foot off the brake when it comes to this and i think you know everybody probably knows this. But the is comprised of thousands of people And even the drug review arm is separated into individual fiefdoms focused on you know different aspects of biology and science and types of drugs etc and each one has its own internal politics. Each one has its own personnel changes in its own kind of regulatory philosophy. It's different between cancer than it is from neuroscience for example and so i guess it's one of those things where reading these tea leaves has kind of maybe run out of clues to offer us and maybe we should all just kind of respected. It's a giant organization and we are on the outside of it.

FDA Alzheimer's Disease Biogen Advisory Committee Cancer
"biogen" Discussed on WBZ NewsRadio 1030

WBZ NewsRadio 1030

01:33 min | 4 months ago

"biogen" Discussed on WBZ NewsRadio 1030

"Biogen Open. You get approval early next month. But it has been a pretty bumpy road up to now scores of failures along the way this treatment, promising to slow the progression of dementia, But because of questionable testing results, it remains a real possibility that the FDA will completely reject that application. So what are we going back to the office anyway? One of the most asked questions of this year, according to a new report, more than half of all companies surveyed while they have no idea, career placement company Challenger, Gray and Christmas finding 17% are already back on campus. Quarter of companies say they plan on getting workers back to the office later on this year, likely at or around Labor Day. Go to the South Coast. Now at 7 27, a police job a police dog, rather getting the job done this week after safely tracking down a lost senior man with dementia. WBC's Tim Dunn has that story. Most of us may only be aware of the power of dog's nose really has well at the dinner table guarding our plates from wandering eyes. But that incredible sense of smell was put to the test this week when Dartmouth Canine officer tear tracked down a loss. Elderly man with dementia, Dartmouth police say on Sunday afternoon, Mattapoisett police requested assistance in locating the nonverbal man. Garbage PD deployed their canine unit consisting of the German shepherd tear in his handler, officer Jared White here was able to track down the elderly man after sniffing some of his clothing. He eventually lead officer White Mattapoisett police officers to the man who was innocently lying down behind a pile of wood. Tim Don WBZ Boston's news radio Mervis Diamond importers welcomes Vera Joe. This weekend only enjoy.

Tim Dunn Jared White Sunday afternoon Challenger 17% Tim Don Vera Joe WBC South Coast Gray FDA this week German this year Dartmouth early next month One Boston This weekend Garbage PD
Will Selecta Biosciences be the Next Top Platform Biotech?

Breaking Biotech

05:38 min | 6 months ago

Will Selecta Biosciences be the Next Top Platform Biotech?

"The first company. I wanted to touch on is news from july lilly and they're huge company. Say like a large mega cap at one hundred and eighty three billion dollars and what they recently presented was the full data set from their molecule demand in alzheimer's disease. And this is a phase two trial looking at this antibody that targets a specific epoch on the amyloid beta approaching and this episode is only visible in established plaques. Now i don't want to belabor the point about the amyloid hypothesis which i've done in previous videos. Suffice to say that a number of different molecules have been attempted in this indication in specifically the mechanism of reducing amyloid plaques. And they've all failed and what we're seeing here is that in this multi center randomized double blind placebo controlled trial. That donna had a significant is what they're showing here in the air score but not a very profound impact on cognition and so they looked at this primary outcome the air score and this is a combination of the as well as the ads. Ads and so eight ask cogs general measure of cognition whereas the ads. I is a measure of activities of daily living. So they did a combined score with that and demanded mobs improvement led to a p value of point zero four so technically significant. But i'm not sure that if they replicated the stayed in a face. Three trout necessarily be positive. It is an interesting thing because when you look at the actual aid. S cog thirteen score. We don't see any significant change. It is better in indiana but not by a significant margin and then the mse score is basically no difference between the two so this is another data point to suggest that perhaps the amyloid beta hypothesis isn't one that these companies should be looking at and the last thing i wanted to show here. Is that the one thing that they do. See a significant change in the amount of amyloid in the brain and so the pet scan here to show that the dynamic treated group has a significant reduction in the amount of amyloid plaque in the brain compared to placebo. So the drug is able to reduce the emily beta plaques. But it's not able to improve cognition really as much as you would expect given the effect is there so i wanted to bring this up because there is an upcoming. Pdf date for biogen's advocating mob and this is going to be a huge movie for the stock and it was originally supposed to be in march but it was delayed until june seventh of this year. So keep your eyes on that. I don't know if i'm going to make any position on it. I think that the fda should not approve it given the results from the advisory committee but given that the so many is on this pdf. I feel like there's a chance at the fda could overlook that and end up approving drug. So it's definitely jairo word. Play and i would treat it as such and proceed likewise so that is eli lilly. I wanna quickly move on to another company in the alzheimer's face called novus and i touched on them in my previous video and what we heard in the last week was that they announced positive face to data and this is interim data showing the nbs for one or another name for the molecule is positive in improved speed and coordination in parkinson's patients. And this is a twenty five day treatment. Nine patients were in the treatment group and five or in the placebo and on the announcement of this data. I think the stock was trading around one hundred fifty maybe two hundred million dollars market valuation and went up to around two fifty three hundred before settling around two hundred and fifty million dollar market cap so big move up in the stock and i'll tell you the data. The ceo explained that the study was power to investigate a difference of twenty to twenty five percent in biomarker levels not to demonstrate efficacy making this data that much more significant so to provide some context. And why i think this is interesting. Is that i in my previous video. Didn't really seem to bullish on a novus and the reason for this is that it reminds me very closely other types of amyloid beta drugs because this drug reduces app the precursor protein to amyloid beta. So my rationale is that if they're targeting the same emily data pathway. Given that there's been so many molecules that have failed previously targeting that pathway. I don't expect that this one is going to be any different now. Having said that. I decided to take a position because we've seen over and over again. That companies have been able to spin face to data in a positive way that leads to these big increases in the sock even though in phase three there's an eventual failure so i decided to take a position in stock and i have been rewarded handsomely so far and i'm going to hold on to see the rest of the phase two data so to get the actual data here in one test that measures the speed of execution. The results were statistically significant. P equals zero point zero four showing that while parkinson's disease patients are slow in coding. Boxes met with an s four. Zero one improves their performance. In these same patients other test that measures coordination showed an improvement in their movements and was almost statistically significant peak will s- appoint zero seven. Then they say in all end. Es up tests performed the placebo group either stayed the same or performed worse than at baseline instead the a b s four zero one group either stayed the same perform better than at baseline and as we know. Md s up drs is a specific tasks that measures severity and progression of the disease.

Alzheimer's Disease Parkinson's Disease Jairo Lilly FDA Biogen Donna Indiana Eli Lilly NBS
Dj vu in Alzheimer's research, and OWS's legacy

The Readout Loud

03:48 min | 9 months ago

Dj vu in Alzheimer's research, and OWS's legacy

"Joe biden is heading to the white house. The us is grappling with an economic crisis and biotech is debating the amyloid hypothesis. Twenty twenty. one is starting off quite a bit like two thousand nine. Thanks in part to ally lilly and some surprising data on a new treatment for alzheimer's disease the biggest story coming out of j. p. morgan this week was news that a lily drug called banana managed to significantly slowed the progression of alzheimer's in small clinical trial. So why this is so notable denham ab like so many failed drugs before it is designed to attack toxic proteins in the brain called amyloid and that was reason enough to reignite the decade plus long argument over whether clearing out amyloid can actually make a difference for patients with alzheimer's disease so before we get into the implications of all that we should summarize what we actually know. Here's what lily disclosed in a study involving two hundred and seventy two patients with early stage alzheimer's those who got to non-arab some of their cognition and function decline. At a rate that was thirty two percent slower than those who got a placebo. The company used a metric called the integrated alzheimer's disease rating scale which we should note is a different measurement than what we've seen in past trials and that's about all the detail we got so far. Lilly said it would present full data at a conference in march. But until then we've only got a press release to go off of so i. I'm curious what you guys think. What are the implications of this. All the caveats that would apply to any alzheimer study. Let alone one this small but it arrives as we await word from the fda on a different Amyloid targeting treatment from biogen called which we spent a lot of time talking about on this podcast and then here comes this lily. News like a comet from the sky. How does this change kind of the state of play of amyloid so to me. This is just it's like deja vu right. it's we sort of fall into into this pattern of just keep recycling. The same arguments about the you know the efficacy of amyloid. Whether you're drugs that target amyloid are effective in alzheimer's and i i don't know what to make of these data. I i mean. I think what it says is that we will be having this debate for years to come. Even after we get a decision on atacama. I totally agree. I mean the sense of deja vu was so strong. I was looking back at articles trying to see what had happened through the years with these drugs targeting beta amyloid and i got back to you know twenty ten. When a lily drug called sima geza stat failed and there was this great npr story actually. Quoting bob langres who at the time was at forbes announced bloomberg my old colleague saying that this was really going to call into question the amyloid hypothesis. This was eleven years ago And we had daybreak on. Cnbc this week to talk with him. He's the ceo of eli lilly. And you know. He was the first one to note. How many failures. They've had in their thirty years of working on alzheimer's disease at the company. I'm focused on on this target One thing he noted that's different about this. Trial is its size. It was small and he said that was the reason he was more optimistic about the signal. They saw that they saw such a strong signal in a small study. Made him feel like it. Had to be an even stronger signal He noted that in the past they had gone to these very large phase three trials because they thought they would have to order to see a signal and here they did this small trial to see if this was even worth pursuing a before going to that big one so i thought that was pretty interesting but i also think we're still arguing over whether amyloid is a cause of alzheimer's or like jeff jonas. The former ceo of sage. Who's still at sage in a different role You know he. He's put it as he thinks. It's more like a scar or a scab where you pull it off. That doesn't fix the underlying wound. And we just don't have those answers yet

Alzheimer's Joe Biden Denham Lilly White House Banana Sima Geza Stat Morgan Biogen Bob Langres Lily Atacama FDA United States NPR Eli Lilly Bloomberg Cnbc
"biogen" Discussed on Breaking Biotech

Breaking Biotech

05:07 min | 11 months ago

"biogen" Discussed on Breaking Biotech

"So i think this is the fact that they have oral presentations. I think is pretty bullish for me. The organizing committees that look at the abstracts have to make a decision whether or not they're going to give an oral presentation or poster presentation usually pick the oral presentations for the more prestigious or exciting data. So for this reason. I think it's worth holding into it holding the stock into the data to see what the readout is now. The company itself is kind of suspect they have diluted over and over again they have done reverse splits to maintain the price of the stock to prevent delisting so. I am excited to no longer. Hold this company so as soon as the update happens from the fifth to the eighth whenever their presentation is i'm gonna sell whether it's positive or negative. I just want out from the company. I think the theory behind their technologies pretty interesting. But i just don't trust a management team in over and over again even if it's a good molecule of the management team sucks. It's a it's tough to make a profit from a lot of those companies. So that's actinium. Wanted to mention that. Because i haven't touched on them quite a while moving on i wanted to give an update on biogen and the reason for this that there was tons of drama surrounding the advocating mab advisory committee and so the ticker symbol for biogen is b. i b. and they trading now at around eight thirty six. I think it might be closer to forty now billion dollar market cap and the drama that we heard is that. The advisory committee took place for the evaluation of education abc in the treatment of alzheimer's disease. And so how. These advisory committees go. Is that two days before the advisory committee date at which point the committee members will actually vote. The briefing documents are released and this is from the fda and it's sort of an evaluation of a a. that was submitted by the company. And the fda's opinion on what the company is presented. So you'll get actual feedback from the fda on what they think about. What biogenic saying about their molecules. So how this works is that everybody gets to read these briefing documents and it gives the public a sense on whether or not the fda's leaning one way or another and kind of prompts. the advisory committee. I would say now what happened after these documents were released. The stock rallied huge off of this news. And the reason for that is that it looked like the fda is extremely positive on approval of added kanuma. And i'm just going to read a couple of quotes on why this is the case overall. The fda tried to be kind of neutral unbiased but in so many of their comments. We see that they're in support of approval. And so i'll just read some of these. Fda agrees that the results from study three. Oh two are highly persuasive. And the study is capable of providing the primary contribution to demonstration of substantial evidence of effectiveness of ad cab than one other quota wanted to read they say that biogen and the fda jointly.

fda biogen alzheimer's disease
"biogen" Discussed on NewsRadio WIOD

NewsRadio WIOD

05:48 min | 11 months ago

"biogen" Discussed on NewsRadio WIOD

"You're not gonna need zoom if you're back in the office and you're gonna be back at the club, and therefore you're not going to need your pellet on anymore and Grubhub. Forget it. You're gonna go out to eat instead, I understand those shorts but explain Cusco. Why is that a short? Central Garden and Pet Boston beer Just because the pandemics over we're not going to be drinking beer anymore. I think we're going to drink even more to celebrate big lots. It's a short Scotts miracle. Gro. The pandemic is gone. So you're going to quit taking care of your lawn? I don't get it yet. This outdoor chipotle a check K 12 Wayfair. Fiver stamps dot com Overstock dot com American Well, Madonna Novavax Lodge attack, Eh, Quinyx? Digital really trust all of these, J. P. Morgan says. You should consider shorting. Now Wait a minute. Why are they say in that? Are they saying people going to quit drinking beer? That's why you should short Boston beer. Nobody's going to go to Costco anymore to buy in bulk. Therefore, he should short Costco due to the end of the pandemic. No J P. We're gonna saying this because relative to the company's profits, The stock is priced too high. And there's a disconnect between the stock price on the company's current and projected profits. And on that basis, they believe the stock's gonna come down in value. It has nothing to do with the pain now make it has everything to do with investor euphoria that is UN. Justified and therefore unsustainable and their point of view. No, I'm not telling you to go short These stocks first. I don't believe in shorting your portfolio. That's a bet. That's a speculation. That's not what I'm here to advise you to do. I'm simply making the point. That you've got some Wall Street heavy hitters, saying we need to temper our enthusiasm. And no better example of this. Of the importance that you not respond with a knee jerk reaction to the momentary news happened in the last week and a half with Biogen. Biogen has been Working on an AL Timers drug for a long time and last week. They got the FDA scientists to say that their drug is safe and effective. This would be the first new treatment for Alzheimer's in more than 20 years. Extraordinarily exciting news on Hey, guess what, on the news by agendas stock, Rose 44%. Now let's just understand why 2.5 Million Americans have Alzheimer's disease and if a third of them were to use this drug Bajans sales would be $36 billion a year, the number one selling drugs Humira and its sales or 20 billion, so this Alzheimer's drug would be the most successful drug of all time. Exciting, isn't it? No wonder the stock jumped 44% in a single day. Yes. What happened two days later. An outside panel of medical experts rejected the FDA is Recommendation. Do you say we try that one again, Huh? They said the evidence wasn't persuasive. 10 of the 11, members of the panel voted against approving the drug and the 11th member said he was uncertain. So that nixed that idea. And Biogen shares fell. 28% now follow this roller coaster. Let's say that you started with $100. And you bought by a Jan and enjoy that. 44% increase. You now have $144 And then two days later, it falls 28%. You're back to one of three. But I know what you're saying. You're saying no, Rick, This isn't a problem. I still got a tiny little profit. I started with 100. I've got 103 after that roller coaster. You know why That's nonsense. Because you didn't buy the stock before the announcement. You probably never even heard of by a genuine did you have no idea that we're working on an Alzheimer's drug or that the FDA panel was going to say they are not to be approved? You bought it after it went up 44% because of the euphoria just in time to catch the 28% decline. So, your 100 bucks Is now on Lee 72. That's my point. We need to get a grip on our emotions in this environment were all charged up due to the election. You're either thrilled with what's going on or you're agitated beyond consolation. You're either very excited about the news of visors vaccine or you're skeptical. We need to put our emotions in check or it's going to lead you to making bad decisions that will harm your ability to achieve your financial goals and maintain your effort. For financial security. And one of the reasons that people love real estate is because it's divorced from all the above nonsense because real estate isn't volatile like stocks. It doesn't go up 44% 1 Day and down 28% the next. It doesn't swing have zigzags like that. That's one real reason that people love real estate because that doesn't have the volatility. That's nonsense. Real estate is volatile. The reason you think it's not is because it's hard for you to know what the value of your house is. Your house is price is not trading in real time. The way you are mutual funds and your IRAs are Houses are not posted in real time, or at least they weren't until Zillow. Zillow now offers those estimate where you can actually see what they say is the value of your house in real time, and people are actually doing this. They're going online on a daily basis to see the latest that Zillow posts there the way that people.

FDA Alzheimer Zillow Biogen Costco Cusco Grubhub Madonna Novavax Lodge Scotts Boston UN Alzheimer's disease J. P. Morgan J P. Quinyx AL Timers Rick
"biogen" Discussed on Radio Boston

Radio Boston

04:53 min | 1 year ago

"biogen" Discussed on Radio Boston

"And you know you talk about how this disease has had disproportionate impact on poor communities in communities of color, and that's true. But so has the lockdown and particularly the closure of schools has negatively impacted communities of color it ways that they might not be able to make up at those particular students may not be able to make up and that's very tragic So you know I think the Republicans are talking a lot about reopening schools about making sure that that the poorest communities are served 'cause the rich kids are sending their kids to private school the rich people so. This hotel has is that. I got to stop their gender so much more. We could debate there but I'm so grateful you came on conservative political analyst Jennifer Per Sarah's thanks for joining us. No problem talk to you soon. As our conversation before the break demonstrated, our political minds are wholly occupied this week with the upcoming elections. But here at Radio Boston stomachs are stuck in the recent past last week to be exact at the Democratic national. Convention. Stayed appetizer Calamari is available in all fifty states the column Comeback State of Rhode. Island cast one vote for Bernie Sanders and thirty four votes for the next President Joe Biden? That is, of course, Joe McNamara The chair of the Rhode Island State. Democratic Committee and we spoke with him on. Radio Boston last week and while that TV moment might have become a social media punchline for McNamara Calamari is serious business many businesses especially the restaurant industry in virtually every state. As been decimated by this pandemic. But on top of that fishing industry in Rhode Island that supplies many of the restaurants with quality seafood products was also devastated. So we got to thinking what is the real story behind? Rhode Island's state appetizer and how did CALAMARI become king of the ocean state well turns out. There is someone who can help us answer that we're GONNA turn to an unlikely column expert, S E Cup, she's a political commentator and host of CNN's S. E. Cup unfiltered a columnist for the New York Daily News and the reporter behind a daily beast expose titled the Rise of Calamari fueled by Rhode Island's dirty Politics Se Cup. Welcome to Radio Boston..

Rhode Island McNamara Calamari Rhode Island State Rhode Boston Radio Boston Joe McNamara political analyst Joe Biden Jennifer Per Sarah Bernie Sanders Democratic Committee New York Daily News S. E. Cup CNN reporter President
"biogen" Discussed on Radio Boston

Radio Boston

04:39 min | 1 year ago

"biogen" Discussed on Radio Boston

"We've got matt on the line from Weymouth. Matt. You're on with me and Jennifer Sarah's what's on your mind. Thanks so much for having me. I my mind right now I got a I got a concern you know. So just a quick background, I was raised conservative I grew up you know in a household that was conservative but we didn't have guns however after watching the RMC last night and I have a hard time figuring out what side of the fence on for instance, you know I do have ties to the cannabis industry. So after listening to the fact that you know if you go into another shutdown, you know we're going to like Kenneth Cannabis sensory stay open as well as you know. Just all around listening to how they were talking about. You Know Trans Rights you know, I'm somebody who has a lot of empathy and respect for people. So I just find myself more and more torn. You know the further these debates on and conventions go on. Thanks for bringing your voice into this match Jennifer. Well. I think it's interesting. I mean in Matt mentioned lockdowns I. Think the Republicans are trying very hard to portray the the Democratic Party is the Party of shutdowns and they're the party of you know they. The Republicans. Want to portray themselves as the party of of reopening and getting America back on track I do think that will resonate with a lot of people who have been very frustrated with the slow pace at the reopening. I WANNA I wanNA talk about some of the rhetoric. Jennifer, we heard a lot of critics of last week's Democratic National Convention or or even pundits supporting it talking about some dark themes that were brought forward and there have been some dark themes brought forward this week to one of the recurring lines of rhetoric has been. The president, as they said in one of the opening speeches, the bodyguard of Western civilization and I wanNA play Kimberly Guilfoil here a trump campaign senior adviser, and now Donald Trump junior's girlfriend talking about how Democrats are seen as a threat to Western civilization. They want to destroy this country and everything that we have fought for and hold dear they want to steal your liberty, your freedom.

Democratic Party Jennifer Sarah matt Kenneth Cannabis Donald Trump cannabis Weymouth senior adviser Kimberly Guilfoil president America
"biogen" Discussed on Radio Boston

Radio Boston

01:45 min | 1 year ago

"biogen" Discussed on Radio Boston

"This valuable new type of research that lets us track at a very granular level housing, how the virus spreads and that can be very useful. For example, if a college trying to figure out how to respond to a little outbreak, they can see whether it came from side. So tell people to stay in more or whether there's really a lot of spread inside and they might need to close down. So it's just a it's a kind of a new kind of DNA forensics that that seems very useful at this moment. Well, thank you both for walking us through it. That's w are common health reporter. Angus, Chen thanks angus. Thank you. And WB are coming health editor Karrie. Goldberg good to talk to you again to thanks. You're welcome. The Republican National Convention Taking Place in Charlotte North, Carolina is unconventional for a number of reasons this year but that isn't stopping the party from pushing its number one agenda item, which is, of course to reelect president trump here is first lady Melania trump making the case for that from the Rose Garden last night and responding to some of the remarks made at last week's Democratic National Convention. I don't want to use this precious time attacking the other side. Because as we saw last week, that kind of talk only serves to divide the country further. I'm here because we need my husband to be our president and commander in chief for four more years. He's what is best for our country. So. Aside, from another term, what is at stake for the president and the Republican Party leading into November, and what does that mean for the voters of Massachusetts we'd like to get your reactions are you a trump supporter and are you watching the RNC this week what do you think is an effective set of messages to you are you on the fence.

president Republican Party Angus RNC Goldberg reporter Charlotte North Rose Garden editor Massachusetts Chen Carolina
"biogen" Discussed on Radio Boston

Radio Boston

05:41 min | 1 year ago

"biogen" Discussed on Radio Boston

"It's not in a traditional scientific journal yet it hasn't been as you say peer reviewed, but it's on what's called a pre print server, which is called Med archive it's spelled med capital ex IV that does screen it's research before it's posted even though they don't do a formal peer review. So it's true that it's sort of not fully cooked, but but but it's cooked enough that I'll eat it personally. and Are we. GonNa stick with me carry. Time where that's great where we can't afford to wait for new science to go through the Peer Review Process and I wonder does that raise questions about the speed of the peer review process. Yes I mean I think we're catching a time when scientific publications are very much influx and that's a big piece of it that the process has traditionally been very slow and you're absolutely right that at a time like this, we do not have time for the typical months and months that it can take to get into a traditional journal, those journals like science and nature and New England Journal of Medicine are still the gold standard in in science and medicine. But the pre print servers sort of St-, more upstart he. Instant online servers have been rising for years and they've become incredibly important during the pandemic. So I'm so for example, with a paper like this, like it's worth noting that this is only a preprinted. But in this case, it doesn't make me question the papers validity and I definitely think that this is one of those things that are going to last long after the pandemic it was something that was ripe for change that papers come out faster I mean if you think about it, why should a paper on cancer wait for months either we need? This process can be sped up and I think this could be a good thing that comes out of the pandemic. and Larry I suppose to you go ahead and guess go ahead I just to jump in here. The this being a pre print doesn't mean it's not going to get peer reviewed early that process is still going to happen. We just get a little window into this information before it's totally through the end of the process. The irony of this. Let me ask both of you. biogen's gotTa be dying at this point as a company is a biotech company here at finds itself in the middle of this study with these results have either of you heard anything from them or heard any reactions from them. Yeah I I have you know biogen as a company? Throughout this whole pandemic in this process have been really eager. To to share their their employees and their data and their own super spreading events with researchers to find out how this happened and further our understanding of how the coronavirus spreads how evolves and how it behaves I. think that's biogen representative told me that they would never knowingly do anything to put their employees or anyone else at harm. And I have to believe that they're honest about that. Given especially given how much they've worked to make this information public. And and I'm. Just. I would add that you know there's definitely an element of bad luck here it and and experts super spreading events say that although there are clear correlates to what a super spreading event will be. It tends to be indoors. It tends to be a lot of people you know hobnobbing closely but but they're also is just an element of pure luck and the only thing I would add is that it does seem as if often in these events, there's one person who has somehow been a personal super spreader. Shedding loads.

New England Journal of Medicin representative Larry pandemic.
"biogen" Discussed on Radio Boston

Radio Boston

03:28 min | 1 year ago

"biogen" Discussed on Radio Boston

"To cope in nineteen complications and so Gatot, says, we need to do better and making sure these communities are better protected from infection because once infectious introduced there, it's almost impossible to stop and the the consequences can be just devastating. Well it sounds like it. Kerry you've over the months participated in a number of our Dr Collins and we often talk about research with the doctors and I because I want to talk about an important caveat here this paper is not yet peer reviewed. It's not published in a scientific. Journal. Decided that change how we should respond to interpret these findings. Well. TC under the fact that this is called a preprinted doesn't concern me for a few reasons. One is that this paper comes from an incredibly impressive bunch of researchers. Another is that even if this individual paper is wrong, it's still part of this growing hill or mountain of evidence that super spreader events are really important in this pandemic but I, think most of all. It's not in a traditional scientific journal yet it hasn't been as you say peer reviewed, but it's on what's called a pre print server, which is called Med archive. It's spelled med capital are ex IV that does screen it's research before it's posted even though they don't do a formal peer review so it's true that it's sort of not fully cooked, but but but it's cooked enough that I'll eat it personally. and Are we. GonNa stick with me carry. Time where that's great where we can't afford to wait for new science to go through the Peer Review Process and I wonder does that raise questions about the speed of the Peer Review? Process. Yes I mean I think we're catching a time when scientific publications are very much influx and that's a big piece of it that the process has traditionally been very slow and you're absolutely right that at a time like this, we do not have time for the typical months and months that it can take to get into a traditional journal, those journals like science and nature and New England Journal of Medicine are still the gold standard in in science and medicine. But the pre print servers sort of St- more upstart he. Instant online servers have been rising for years and they've become incredibly important during the pandemic. So I'm so for example, with a paper like this, like it's worth noting that this is only a preprinted. But in this case, it doesn't make me question the papers validity and I definitely think that this is one of those things that are going to last long after the pandemic it was something that was ripe for change that papers come out faster. I mean if you think about it, why should a paper on cancer wait for months either we need? This process can be sped up and I think this could be a good thing that comes out of the pandemic. and Larry I suppose to you go ahead and guess go ahead I just to jump in here. The, this being a pre print doesn't mean it's not going to get peer reviewed eventually that process is still going to happen. We just get a little window into this information before it's totally through the end of the process. The irony of this. Let me ask both of you. biogen's gotTa be dying at this point as a company is a biotech company here at finds itself in the middle of this study with these results have either of you heard anything from them or heard any reactions from them..

Dr Collins New England Journal of Medicin Larry Gatot Kerry pandemic.
"biogen" Discussed on WBZ NewsRadio 1030

WBZ NewsRadio 1030

01:40 min | 1 year ago

"biogen" Discussed on WBZ NewsRadio 1030

"There the governor is urging the FDA and CDC to approved the state's request to allow more hospitals and labs to conduct the testing in Pittsfield Kevin Tunnicliffe WBZ Boston news radio and we have new numbers tonight on the corona virus from the health department they say we have one hundred eight total cases right now here in Massachusetts six confirmed by the CDC the rest presumptive positive eighty two of those cases connectors that Biogen meeting last month in Boston of course we've been hearing that a lot of school districts making the decision to shut down got a virtual learning a two week closure in effect starting tomorrow for several schools including Lexington Belmont Arlington and Winchester and we learned today as well that effort schools are shutting down for thirty school days that means kids will go back on April twenty seventh we have an extensive list on our website of closures we are constantly updating this you can check it out right now W. B. C. ten thirty dot com about six oh six former vice president Joe Biden spoke today about the outbreak the Democratic Front runner criticizing not only president trump's response to corona virus but the very way he operates his administration saying the president's decisions to distance the U. S. from other countries and allies has left the U. S. fighting corona virus from within instead of overseas this administration has left us woefully unprepared for the exact crisis we now face the trump campaign quickly hit back at bite in saying he's trying to score political points and Stoke fears it also defended the president's response to corona virus Markram Alard ABC news we also heard today from his campaign rival senator Bernie Sanders in Vermont claiming the threat of corona virus is on the scale of a major war he's.

Bernie Sanders senator vice president Winchester Biogen Kevin Tunnicliffe Pittsfield Vermont FDA Stoke president trump Joe Biden Lexington Belmont Arlington Boston Massachusetts CDC
"biogen" Discussed on The Readout Loud

The Readout Loud

08:00 min | 1 year ago

"biogen" Discussed on The Readout Loud

"It is probably fair to say that. This year's big story in biotech is biogen's decision to take a once dismissed treatment for Alzheimer's disease and file it for FDA approval this week at a big conference in San Diego. That story got a little more interesting so to catch up as quickly as possible. Back in March biogen terminated two studies of a drug called Educating Mab after concluding that they were probably going to fail in terms of treating Alzheimer's disease then in October the company shocked the world. By saying that after inspecting the data they now believed not only that the studies were positive but they were positive enough to convince the FDA to approve the drug now considering the fact that roughly one hundred percent of potential. Alzheimer's drugs have failed over the past twenty years. That claim spark some skepticism. And that's what leads us to San Diego where Bison finally presented some detailed data on Canada mob meant to strengthen its case. Good morning everybody. So you've heard my name is Samantha. But headline and I work at biogen and I'm going to report morning. The top line data from emerge and engage which were two identically designed studies to evaluate patients with early Alzheimer's Disease. Our colleague Matt. Hooper joins us to talk about what we learned what we didn't learn and what remains deeply confusing about biogen's drug matt. Thanks FOR COMING. Back on the PODCAST. Thanks for having me so matt as we mentioned. There were a ton of unanswered questions coming into this presentation. What did we learn about education that we didn't already know in broad strokes not that much? We learned a lot of specific data. Points kind of help fill in the picture but the pictures a lot like what we learned when. Biden said it would make this decision. The standard here has traditionally been that you need to positive studies but the FDA has said it will consider a positive study in supportive data in the high dose group in one of biogen studies. There's a statistically significant benefit in the other there is not. They presented some analyses which were much clearer than what we've seen previously about how they'd made a change in those studies that they think resulted in patients getting a higher dose and they showed us in more detail what the curves of those studies like in the patients who only got that high dose and really this hinges on whether does that count as strong of supporting data to make the FDA take these two disparate results and believe that. There's enough benefit to approve. Well so and that's kind of the crux of biogen's case here is that there's one study that looks extensively positive at that. High Dose Group. Mad that you mentioned and there's another that is you know looked at I would say traditionally very very negative but biogen sliced and diced the date a little bit and isolated a certain patient population did it says has a positive result and thus zoom out far enough to high dose seems to be an effective medicine so that was what incurred a lot of skepticism that we were talking about Matt. Do you feel like the added detail that biogen presented. This week did much to address those concerns or might actually have worked to convince some people who were on the fence or who were negative ahead of time so I actually don't think they sliced and diced it is post hoc and so there are all sorts of problems but they really only looked at one thing which is after they this protocol amendment. What do the data look like? I think they helped start to describe their case. But I expect should this get to FDA panel that there will be a lot more questions in one thing that I found kind of fascinating about the presentation was there weren't any statisticians on stage. The clinical trial people who were going to raise concerns about this or not really about Alzheimer's. They're really about what happens when you stop study early. And then you analyze the results and some of the results are imputed and you're relying on an after the fact analysis to understand whether or not the data positive and they started to make that case but really it was only the tail end and I felt like that particular issue wasn't something that the experts on stage interrogated very much and that's where all my questions are. What about the risk side of the equation? Obviously you have benefits and you have risks. Did we learn anything? Today about the Anaconda Mab safety data that changes the perception of the drug as it relates to its efficacy. I think yes it in exactly this context. We understood what the safety risks were with educated map of Alzheimer's drugs of its type where the most common often serious side effect is a swelling of the brain that can lead to pain and nausea and other affects so we saw that in that High Dose Group. That biogen says is the population. You should really look at when deciding whether educated networks about thirty five percent of people experience that brain swelling so that with the seriousness of Alzheimer's. You can look at that however way you might like. I think you know Adam to your point the way the FDA looks at this is risk benefit and the the trade off there in. So I think the question that I still have going forward and that I think the FDA will be digging into deeply is is the benefit that we've seen enough to justify that risk and so if you look again at the the patient population that biogen has isolated. You're talking about a benefit of about point five points on a three point scale of dementia which is to say patients who got the drug did about point five points better than the ones who got placebo. What does that point five translate to in real life clinically for people who have Alzheimer's? I think that remains the key question. We didn't learn anything that suggests educated is is too dangerous or has safety risks. We didn't know about. I think what we really laid out before us. Now is the risk benefit question in raw numbers. And what are the big mysteries remaining well? I really think it's GonNa be interrogating this this. How much do we believe in these supportive data and it really does come down to that? But that's going to require a lot of digging into the nuts and bolts of this trial so the other team here as we mentioned there are two studies one ostensibly positive one positive depending on who you listen to you and to a lot of experts that we've all heard from in the weeks months since by Jimmy. This announcement they say. Wow What an interesting hypothesis identified. What a great way to justify a third study to really isolate those patients you think will benefit tested in placebo controlled fashion. And then you'll really know and you know Matt. You had the chance to talk to you. Alexandra who is the top scientists? Stop doctor over at biogen at the stat summit last month. How did he react to this concept of? Why don't you just run a third study and bring that to the FDA? Well he said that biogen could end up having to run a third study and I believe. He said that he thought the company would do it. He also said quote which a lot of people have reacted to. Which is that you know. Here's the decision that the FDA is going to have to make. Do we believe there is enough evidence to approve it now. Or do we ask the companies to do another trial. Wait five years and how many people have to get to mend in that time period so biogen's trying to walk a fine line of pushing on the need for a drug like this but trying to be respectful of the FDA process. Their answer is look if we have to do another trial. That's going to take a long time. Do you really WanNa wait to have a drug in a lot of the analysts debates about this for people who are favoring it mentioned all the political pressure that will be on the FDA in order to try and improve the medicine and the flip side of that is. Do you want to give a drug that stand a chance of not working? Do you want to create false hope at no small economic costs not only from the drug? But the fact that this drug has to be infused which means that you'll have a lot of people kind of going into an outpatient setting with nurses you have to pay and other factors like that Matt as always. Thanks for joining us. Thanks for having me talk soon. So as we mentioned before Rebecca.

biogen FDA Alzheimer Matt High Dose Group Alzheimer's disease San Diego Canada Samantha Biden Hooper Rebecca Adam Jimmy Alexandra nausea
"biogen" Discussed on Bloomberg Radio New York

Bloomberg Radio New York

07:54 min | 2 years ago

"biogen" Discussed on Bloomberg Radio New York

"Thank you so much. You're listening to Bloomberg BusinessWeek Jason Kelly alongside Carol Massar spoon. Berg radio. Freefall, and that's exactly what's happening to shares of Biogen today. Plummeting after the biotech giant said that it's experimental Alzheimer's drug was unlikely to be effective and that it was halting its research. It's another setback for drugmakers efforts overall to find a therapy for the Amit the company's stock as I mentioned Biogen down about a third in terms of its overall value. Let's get into the SEC Gunnar Watana. He is senior biotech analyst at Bloomberg intelligence. Our in house group of analysts he's here in our Bloomberg interactive brokers studio, Brian's corny also with us biotech and pharma, Alison Baird. He's joining us on the phone here in New York. I want to kick it off with you. So obviously a major disappointment kind of this. I walked into the studio said was this expected. Well, I think people are hoping for this situation to play out, but sadly histories repeated itself Carol, I mean, if you look back this is about six major product that's failed in phase three that targets the same mechanisms pretty far along. This is exactly it's interesting face one data that they got people excited about it. I really wish history taught us a lesson and here, but I mean it on its merits it did look like it had some sort of activity was it had side effects, which indicative as well. But. Did not align. So Brian come on in here. I mean, if you're an investor and you're looking at this. What what do you do at this point? Obviously, the answer that many people have is you sell the stock but longer term what does this mean? Yeah. So I mean for for for Biden specifically, I mean, I think people really have to start putting fresh eyes on it. I mean, this was a big hope for this management team. They leverage to the story really to a lot of people surprise is not really aggressively pursuing in a or b d that would potentially diversify away from a risk of failure. But you know, in essence elaborate in themselves even more to this beta amyloid hypothesis, so we wrote in our note today, we think. There's a chance for this to be oversold as people really struggle with confidence in management, but management credibility. What are the options for this team to even do here at this point to kind of reignite the story NS franchise, but it hasn't really been growing stable for now. But it's more competitive they've had a great asset in a drug called spin Roger for SMS, but that seemed to approaching the peak of its growth Herve as well. And there's certainly a lot of competition there. So right you maintain neutral reading on the stock. You know, we think it's going to be hard for investors to kind of find a floor that they're comfortable with. I do feel like there's two stories here. I feel like there's the one story about all these drugmakers trying to figure out a way how to treat Alzheimer's, and they've all been on a similar path in terms of a drug in its treatment and all of them so far have failed. So there's that story. And then there's also the story of okay? So what does this mean for Biogen going forward? Yeah. I mean to Brian's point as well. If you look at the catalyst horizon that in the next couple of years, but by doesn't really not a lot that could get me excited here. I mean, doesn't emit as Assad one acid last as maybe some stroke data that can come out of a Japanese trial, but the multiple sclerosis data that could come out in the middle of two thousand twenty but did this is kind of a kind of a bleak outlook in terms of really moving Catholic. So the company has some cash United has it ended two thousand eighteen but about two point five billion dollars in the Bank. Maybe take about a billion off for that for the for the reason the shelf night star. But now they need to start deploying the capital, and maybe maybe go on the road and set buying something here to really help them out. Well, I want to pick up on exactly that point Brian. What would they buy what's first sale at this point? And I think there's where there are going to be really critical of them, essentially, not doing a number of deals that would have made sense for companies that have had meaningful meaningful steps and valuation. So I mean, the names that are generally floated out there that make a lot of sense and sort of the CNN field neuro Cran NBA acts with recovers PT, which we also cover saints therapeutics. I just got an approval this week all of these companies had really significant valuation inflections over the last couple of years. They all make sense four by John. You know, at this point, the the numbers, actually, overshot what Biden would be capable of pain. Probably not in most of the instances. I think again, the issue is given how how management's performed over the last couple of years into this status at in a will investors, give them any credibility, even doing aquisition at all? Or is this a situation where you know, we're not going to see a resolution under this management. Team or even with by John as a free standing, and I just want to point out. Neuro current is up about six point two percent. Sage is up about three and a half percent. So the expectation is these could be some of the names, they both medicines apparently approved for neurological conditions that would kind of fit with Biogen's remaining core franchises, you mentioned in terms of MS. How quickly does Biogen have to do something? And is it done? This is just done. Yeah. I don't I don't expect to see anything that could save it at this point. I'd also suggest that the has some other assets in Alzheimer's as well. It's developing something with a company Eisai called D N two zero one. We went very convinced by the phase to data by that, you know, this this this whole amyloid hypothesis is really taking a blow here. So. The first company to pursue this strategy six around. I'd probably the six. Yeah. So so, yeah, maybe maybe there's some other modalities that you could probably target mean they have something in the pipeline that targets towel and a couple of others. But right now, I I would temporal my expectations on what on what the Alzheimer's pipelines going to how quickly do they do need to something. I mean. As as long as they don't have anything in the pipeline intensive catalysts. Not is not a good story and without getting too deep into the science, which I inevitably wouldn't understand. Why has this been such an elusive target? It's I've seen very complicated disease. Brian, but they're not alone in essentially failing here, right? Yeah. That's true. I mean, you know, we sorta cheekily tweeted some comments around how people keep coming back to the beta amyloid hypothesis even after every failure saying, oh, but this time it's different. It's different. I mean. I mean, frankly, it's because there's just not other ideas walking Alzheimer's, I think it's a black box disease. We don't understand it. Well, this has been the primary biological hypothesis. And despite all the clinical failures, I think the scientific community is just holding on for whatever they can identify that might play a role in the disease here. Unfortunately, it continues to be an area where investment apple just got sucked into a big void right seek. I have to think that investors. I mean, they want this to be true. Right. I mean, this is probably one of the highest profile most befuddling things that we're facing as a society. So many people have to deal with this. And I have to think there's some emotion tied up in this as well absolute Gammon, if you look at what d- projections for not just cost of treating patients with Alzheimer's who once you get to really isn't anything that that's out that modifies the disease, but it's not just that. It's also the the caregivers to the actual financial and economic impact on society.

Biogen Brian Alzheimer Carol Massar Biden Bloomberg John New York Bloomberg interactive brokers Bloomberg intelligence Gunnar Watana Alison Baird analyst Amit Jason Kelly CNN Assad Roger
"biogen" Discussed on MAD MONEY W/ JIM CRAMER

MAD MONEY W/ JIM CRAMER

01:56 min | 3 years ago

"biogen" Discussed on MAD MONEY W/ JIM CRAMER

"Because since then it's plummeted two hundred eighty nine dollars the rhymer general is all about i lee that was the revolutionary macular degeneration drug still makes best sixty percent of the company's sales now at least the slow but the big potential competition from though vardis in rooks come has been trying to find their next big thing they had an interesting anticholesterol drug where the partner with sanofi but it's been a bit of a disappointment that's port because a competition for managing but also been hard for a lot of doctors to figure out what to do with it even though i think it's a great truck still coming just announce a new play in the jumpstart sales by laurie drugs price so where nece program jet on this new treatment that was approved last year so far the sales of this one hadn't been strong as i'd like still there's a lot going on the pipeline including promising skin cancer drug that's face to resentments a lot of shots on goal here the main virtue to the four horsemen though they're incredibly cheap by jim sells for less than eleven times next year's earnings for do we do have we have for ten generals a little more expensive fourteen times earnings but you give it to pay for and you know what cheap matters this is the reason biogen cell gene regenerate help so much better than you might have expected it's the most recent quarters even as themselves were almost universally panned by the endless so yeah the four horsemen of biotech aren't the growth powerhouses that used to be but the trading like the world has come to an end at least in the case of regeneration the numbers just aren't that bad people and of course grow could still reignite with the right combination of new drugs in the pipe bottomline these big biotechs are hated because they've lost all the characteristics great stories and that would bother me except that they trade like value stocks i think biogen general are worth checking out right now juliet associated made big longterm bet cancer therapy but it'll be years before we know those bets will pay off i say no thank you at least for the moment much money at many relationships built on trust what is it lacking when it comes to this market and the.

rooks partner sanofi skin cancer juliet two hundred eighty nine dollar sixty percent
"biogen" Discussed on MAD MONEY W/ JIM CRAMER - Full Episode

MAD MONEY W/ JIM CRAMER - Full Episode

01:56 min | 3 years ago

"biogen" Discussed on MAD MONEY W/ JIM CRAMER - Full Episode

"Because since then it's plummeted two hundred eighty nine dollars the rhymer general is all about i lee that was the revolutionary macular degeneration drug still makes best sixty percent of the company's sales now at least the slow but the big potential competition from though vardis in rooks come has been trying to find their next big thing they had an interesting anticholesterol drug where the partner with sanofi but it's been a bit of a disappointment that's port because a competition for managing but also been hard for a lot of doctors to figure out what to do with it even though i think it's a great truck still coming just announce a new play in the jumpstart sales by laurie drugs price so where nece program jet on this new treatment that was approved last year so far the sales of this one hadn't been strong as i'd like still there's a lot going on the pipeline including promising skin cancer drug that's face to resentments a lot of shots on goal here the main virtue to the four horsemen though they're incredibly cheap by jim sells for less than eleven times next year's earnings for do we do have we have for ten generals a little more expensive fourteen times earnings but you give it to pay for and you know what cheap matters this is the reason biogen cell gene regenerate help so much better than you might have expected it's the most recent quarters even as themselves were almost universally panned by the endless so yeah the four horsemen of biotech aren't the growth powerhouses that used to be but the trading like the world has come to an end at least in the case of regeneration the numbers just aren't that bad people and of course grow could still reignite with the right combination of new drugs in the pipe bottomline these big biotechs are hated because they've lost all the characteristics great stories and that would bother me except that they trade like value stocks i think biogen general are worth checking out right now juliet associated made big longterm bet cancer therapy but it'll be years before we know those bets will pay off i say no thank you at least for the moment much money at many relationships built on trust what is it lacking when it comes to this market and the.

rooks partner sanofi skin cancer juliet two hundred eighty nine dollar sixty percent